Indevus Pharmaceuticals: Premium Company Profile
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- Overview - page 1
- Catalyst - page 1
- Summary - page 1
- Table of Contents - page 3
- Table of figures - page 4
- Table of tables - page 5
- Company Structure - page 6
- Company Overview and Key Facts - page 6
- Business Description - page 7
- Landmark Products and Services - page 7
- Sanctura - page 7
- Landmark Products and Services - page 7
- History - page 8
- M&A History - page 11
- Valera Pharmaceuticals - page 11
- M&A History - page 11
- Locations and Subsidiaries - page 12
- Company Financials - page 13
- Stock Market Performance - page 13
- P&L - page 15
- Balance Sheet - page 18
- Cash Flow - page 18
- Business Segment Performance - page 19
- Products & Services - page 21
- Marketed Products - page 21
- Sanctura - page 21
- Sarafem - page 21
- Vantas - page 22
- Delatestryl - page 22
- Supprelin-LA - page 22
- Pipeline Products - page 23
- In-house Pipeline - page 23
- Sanctura XR - page 23
- Valstar - page 23
- Nebido - page 24
- PRO 2000 - page 24
- IP 751 - page 24
- Pagoclone - page 24
- Collaboration Pipeline - page 25
- ALKS 27 - page 25
- In-house Pipeline - page 23
- AC Forecast Product Sales - page 26
- Marketed Products - page 21
- Competitors and Strategic Business Relationships - page 29
- Key Competitors - page 29
- Key Suppliers - page 30
- Key Clients - page 31
- Shareholding Structure - page 33
- Strategy - page 34
- Company View - page 34
- Corporate Strategy - page 36
- SWOT Analysis - page 38
- Overview - page 38
- Strengths - page 39
- Licensing agreements - page 39
- Sanctura and Sanctura XR - page 39
- Weaknesses - page 40
- Lack of manufacturing capabilities - page 40
- Opportunities - page 41
- Marketing approvals - page 41
- Acquisition of Valera Pharmaceuticals - page 41
- Threats - page 43
- Product liability litigation - page 43
- Value Chain Analysis - page 44
- Overview - page 44
- Discovery and Product Development - page 44
- Manufacturing - page 45
- Sales - page 45
- Scorecard - page 46
- Overview - page 46
- Scorecard Analysis - page 47
- Key Employees - page 48
- List of Key Employees - page 48
- Key Employee Biographies - page 49
- Glenn L Cooper - page 49
- Michael E Hanson - page 49
- Stephen C McCluski - page 50
- David B Sharrock - page 50
- Thomas F Farb - page 50
- Noah D Beerman - page 51
- Mark S Butler - page 51
- Dale Ritter - page 51
- Michael W Rogers - page 52
- Bobby W Sandage - page 52
- Michael W Rogers - page 52
- Kurt W Lewis - page 53
- Financial and Operational Overview - page 54
- Financial and Operational Overview - page 54
- APPENDIX - page 57
- Ask the analyst - page 57
- Datamonitor consulting - page 57
- Disclaimer - page 57
- List of Tables
- Table 1: Indevus- Key Facts - page 6
- Table 2: Indevus- Locations and Subsidiaries - page 12
- Table 3: Indevus - Year-End Share Price and Market Capitalization, 2002-2006 ($) - page 13
- Table 4: Indevus- Key Events Impacting Share Price Performance - page 14
- Table 5: Indevus- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 15
- Table 6: Indevus- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) - page 17
- Table 7: Indevus - Balance Sheet, 2002-2006 ($ Mn) - page 18
- Table 8: Indevus - Cash Flow, 2002-2006 ($ Mn) - page 18
- Table 9: Indevus- Revenue Breakdown, 2002-2006 ($ Mn) - page 19
- Table 10: Indevus- Marketed Products - page 21
- Table 11: Indevus- In-house Pipeline Products - page 23
- Table 12: Indevus- Collaboration Products - page 25
- Table 13: Indevus- Forecast Sales, 2006-2010 ($ Mn) - page 26
- Table 14: Indevus- Key Competitors - page 30
- Table 15: Indevus- Key Suppliers - page 31
- Table 16: Indevus- Key Clients - page 32
- Table 17: Indevus- Key Shareholders - page 33
- Table 18: Indevus- SWOT Analysis Summary - page 38
- Table 19: Indevus- Value Chain Analysis - page 44
- Table 20: Indevus- Scorecard - page 46
- Table 21: Indevus- Key Employees - page 48
- Table 22: Indevus - Financial and Operational Overview - page 55
- List of Figures
- Figure 1: Indevus- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 16
- Figure 2: Indevus- Key Strategic Revenues, 2002-2006 ($ Mn) - page 20
- Figure 3: Indevus- Key Strategic Revenues, 2006-2010 ($ Mn) - page 28
Other users found this report page using the following search terms: indevus pharmaceuticals w rogers michael revenue 49 profile indevus sales
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.